Detalhe da pesquisa
1.
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron.
iScience
; 26(4): 106323, 2023 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36925720